# Pharmaceutical-Grade Methylene Blue Trihydrate (MB·3H₂O)
## Comprehensive Clinical Evidence Evaluation for NTRPX Systems

**Document Version:** 1.0  
**Date:** January 23, 2026  
**Classification:** Internal R&D Evaluation  
**Compound:** Methylene Blue Trihydrate (MB·3H₂O), ≥99.5% HPLC purity  
**Chemical Name:** Methylthioninium chloride trihydrate

---

## Executive Summary

**RECOMMENDATION: DO NOT INCLUDE IN NTRPX SYSTEMS**

Pharmaceutical-grade methylene blue presents a compelling theoretical mechanism but **fails to meet NTRPX standards** for three critical reasons:

1. **Insufficient independent replication** of cognitive enhancement effects in healthy adults
2. **Zero human RCTs** demonstrating athletic/physical performance benefits
3. **Serious drug interaction profile** (MAO-A inhibition) creating unacceptable liability for a consumer product

While the mechanistic rationale is scientifically elegant and the compound has legitimate medical applications, the evidence base does not support inclusion in All Systems Go (Boost, Sustain, Recover) or Sprint Systems.

---

## Table of Contents

1. [Compound Overview](#1-compound-overview)
2. [Mechanism of Action](#2-mechanism-of-action)
3. [Clinical Evidence Hierarchy](#3-clinical-evidence-hierarchy)
4. [Safety Profile & Contraindications](#4-safety-profile--contraindications)
5. [NTRPX Systems Fit Analysis](#5-ntrpx-systems-fit-analysis)
6. [Verdict & Rationale](#6-verdict--rationale)
7. [References](#7-references)

---

## 1. Compound Overview

### Identity
| Property | Value |
|----------|-------|
| Chemical Formula | C₁₆H₁₈ClN₃S·3H₂O |
| Molecular Weight | 373.90 g/mol (trihydrate) |
| CAS Number | 7220-79-3 (trihydrate) |
| Appearance | Dark green crystalline powder |
| Solubility | Freely soluble in water (blue solution) |
| pKa | ~0 (strongly basic) |

### Regulatory Status
- **FDA Status:** Grandfathered drug; approved for methemoglobinemia (Provayblue®)
- **WHO Essential Medicines List:** Yes (for methemoglobinemia, malaria)
- **WADA Status:** NOT prohibited
- **Supplement Status:** Sold as "nootropic" supplement without FDA oversight

### Historical Context
Methylene blue was synthesized in 1876 as a textile dye, becoming the first fully synthetic drug used in medicine. Paul Ehrlich and Ramón y Cajal used it as a supravital nervous tissue stain in the 1890s. It has legitimate medical applications for methemoglobinemia, carbon monoxide poisoning, cyanide poisoning, and vasoplegic syndrome.

---

## 2. Mechanism of Action

### 2.1 Primary Mechanism: Mitochondrial Electron Cycling

Methylene blue's purported nootropic effects derive from its unique redox chemistry in mitochondria:

```
┌─────────────────────────────────────────────────────────────────┐
│               MITOCHONDRIAL ELECTRON TRANSPORT CHAIN            │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│   NADH → Complex I → CoQ → Complex III → Cyt c → Complex IV → O₂│
│              ↓                                    ↑             │
│         [electron                            [electron          │
│          leakage]                             donation]         │
│              ↓                                    ↑             │
│            ROS ←──────── MB ──────────────────────┘             │
│                     (alternative                                │
│                      electron                                   │
│                      carrier)                                   │
│                                                                 │
│   MB accepts electrons from NADH, bypasses Complexes I-III,     │
│   donates directly to cytochrome c → increases Complex IV       │
│   activity → enhanced ATP production + reduced ROS              │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

**Key biochemical effects at LOW doses (0.5-4 mg/kg):**
- Increases cytochrome c oxidase (Complex IV) activity by up to 138%
- Increases cellular oxygen consumption by up to 70%
- Boosts ATP production by approximately 30-40%
- Reduces superoxide/ROS generation
- Upregulates Nrf2/ARE antioxidant signaling

### 2.2 Hormetic Dose-Response (CRITICAL)

Methylene blue exhibits a **biphasic (hormetic) dose-response curve**—the same property that makes it mechanistically interesting also makes it dangerous in consumer products:

```
        ↑ Benefit
        │
        │           ╭───────╮
        │          ╱         ╲
        │         ╱           ╲
        │        ╱             ╲
        │       ╱               ╲
   0────┼──────╱─────────────────╲────────────────→ Dose
        │                         ╲
        │                          ╲
        │                           ╲
        ↓ Harm                       ╲____

        └──┬──┘    └────┬────┘     └────┬────┘
         Low      Therapeutic        High
       (<0.5)     (0.5-4 mg/kg)    (>7 mg/kg)
```

| Dose Range | Effect | Mechanism |
|------------|--------|-----------|
| **0.5-4 mg/kg** | Beneficial | Electron donation, enhanced ETC efficiency |
| **4-7 mg/kg** | Diminishing returns | Approaching saturation |
| **>7 mg/kg** | Harmful | Electron theft from ETC, pro-oxidant, toxicity |
| **>10 mg/kg** | Dangerous | Paradoxical methemoglobinemia, hemolysis |

**Implication for NTRPX:** The narrow therapeutic window leaves minimal margin for error. Individual variation in absorption, metabolism, and body weight means a "one-size-fits-all" dose is inherently problematic.

### 2.3 Secondary Mechanisms

| Pathway | Effect | Relevance |
|---------|--------|-----------|
| **MAO-A Inhibition** | Increases serotonin, NE, DA | CREATES DRUG INTERACTION RISK |
| **Nitric Oxide Synthase** | Inhibits NOS at high doses | May reduce blood flow at high doses |
| **Guanylate Cyclase** | Inhibits cGMP production | Antidepressant mechanism |
| **Tau Aggregation** | Inhibits tau protein aggregation | AD research focus |
| **Amyloid-β** | May reduce Aβ accumulation | AD research focus |

---

## 3. Clinical Evidence Hierarchy

### 3.1 Summary Evidence Table

| Evidence Type | Count | Quality | Relevance to NTRPX |
|---------------|-------|---------|-------------------|
| Meta-analyses in healthy adults | 0 | N/A | ❌ None exist |
| Independent RCTs (healthy cognition) | 0 | N/A | ❌ All from single lab |
| RCTs from Gonzalez-Lima lab | 2-3 | Moderate | ⚠️ No independent replication |
| RCTs in disease states (AD, PTSD) | 4-5 | Mixed | ⚠️ Disease, not optimization |
| Exercise/performance RCTs | 0 | N/A | ❌ Zero studies |
| Preclinical (animal/in vitro) | 50+ | Good | ⚠️ Mechanism established |

### 3.2 Key Human Studies

#### Study 1: Rodriguez et al. 2016 (THE Primary Evidence)
**Publication:** Radiology, 281(2):516-26 [PMC5084971]  
**Design:** Double-blind, randomized, placebo-controlled  
**Population:** n=26 healthy adults (ages 22-62)  
**Intervention:** Single dose 280mg oral USP methylene blue (~4 mg/kg)  
**Outcomes:**
- Memory retrieval improved by 7% (P=0.01)
- Increased fMRI activity in bilateral insular cortex during sustained attention
- Increased fMRI activity during short-term memory tasks

**Strengths:**
- Rigorous design (double-blind, placebo-controlled)
- fMRI biomarker confirmation
- Used USP-grade pharmaceutical MB

**Limitations:**
- **Very small sample (n=26)**
- **Single research group (no independent replication)**
- **Acute study only (1 hour post-dose)**
- **No long-term or chronic dosing data**

**NTRPX Assessment:** This is the ONLY high-quality RCT showing cognitive enhancement in healthy humans. A single small study from one lab is insufficient for NTRPX standards.

---

#### Study 2: Functional Connectivity Study (Rodriguez et al. 2017)
**Publication:** Neuroimage [PMC5018244]  
**Design:** Double-blind, randomized, placebo-controlled  
**Population:** n=28 healthy adults  
**Intervention:** Single dose 280mg oral methylene blue  
**Outcomes:**
- Enhanced resting-state functional connectivity
- Modulated task-related network deactivation
- **NO significant cognitive performance improvement** (only neural correlates)

**NTRPX Assessment:** Supports mechanism but did NOT show behavioral/cognitive benefit.

---

#### Study 3: Fear Extinction (Telch et al. 2014)
**Design:** RCT  
**Population:** n=42 subjects with claustrophobia  
**Intervention:** 260mg/day methylene blue  
**Outcomes:**
- Improved fear extinction at 1-month follow-up
- Improved contextual memory

**NTRPX Assessment:** Disease state (phobia), not cognitive optimization in healthy individuals.

---

#### Study 4: PTSD (Zoellner et al. 2017)
**Design:** RCT  
**Population:** n=26 patients with PTSD  
**Intervention:** 260mg daily for 3 months  
**Outcomes:** Moderate cognitive-enhancing effect vs. waitlist control

**NTRPX Assessment:** Disease state, waitlist control (not true placebo), small sample.

---

#### Study 5: Alzheimer's Disease Phase II (Wischik et al. 2015)
**Design:** RCT, 24 weeks  
**Population:** n=321 mild-moderate AD patients  
**Intervention:** 69, 138, or 228 mg/day methylthioninium chloride  
**Outcomes:**
- Patients with moderate AD: ADAS-cog improved 5.42 points vs. placebo
- Patients with mild AD: NO significant cognitive benefit
- Reduced decline in cerebral blood flow

**NTRPX Assessment:** Disease state (AD). Notably, **mild AD showed no benefit**—suggesting MB may only help impaired, not optimal, cognition.

---

#### Study 6: Postoperative Cognitive Dysfunction (Deng et al. 2021)
**Design:** Open-label RCT  
**Population:** Elderly patients undergoing major non-cardiac surgery  
**Intervention:** 2 mg/kg IV methylene blue  
**Outcomes:** Reduced incidence of postoperative delirium and cognitive dysfunction

**NTRPX Assessment:** Disease state (surgery-induced cognitive impairment), IV administration.

---

### 3.3 Exercise & Physical Performance Evidence

**STATUS: ZERO HUMAN RCTs**

| Claim | Evidence Level | Source |
|-------|---------------|--------|
| "Boosts ATP production" | Preclinical/mechanistic | Cell culture studies |
| "Improves endurance" | Theoretical | Extrapolated from mitochondrial mechanism |
| "Reduces muscle fatigue" | Theoretical | No human performance studies |
| "Enhances oxygen utilization" | Preclinical | Rat brain studies |
| "Speeds recovery" | Theoretical | No human studies |

**Critical Finding:** Every performance claim in the supplement industry is based on extrapolation from: (1) mitochondrial mechanisms established in cell culture, or (2) cognitive studies that measured fMRI, not physical performance. **No study has measured VO2max, time to exhaustion, power output, or any athletic metric.**

---

## 4. Safety Profile & Contraindications

### 4.1 CRITICAL: MAO-A Inhibition & Serotonin Syndrome

**This is the disqualifying safety concern for NTRPX integration.**

Methylene blue is a **potent reversible MAO-A inhibitor** at nanomolar concentrations (Ki for MAO-A inhibition is in the nanomolar range). This creates severe interactions with:

| Drug Class | Examples | Interaction Severity |
|------------|----------|---------------------|
| **SSRIs** | fluoxetine, sertraline, escitalopram | ⛔ LIFE-THREATENING |
| **SNRIs** | venlafaxine, duloxetine | ⛔ LIFE-THREATENING |
| **MAOIs** | phenelzine, selegiline | ⛔ LIFE-THREATENING |
| **TCAs** | clomipramine, amitriptyline | ⛔ SEVERE |
| **Opioids** | tramadol, meperidine, fentanyl | ⛔ SEVERE |
| **Other** | dextromethorphan, buspirone, St. John's Wort | ⚠️ MODERATE-SEVERE |

**FDA Black Box Warning (2011):** The FDA issued a safety communication warning of serious CNS reactions when methylene blue is given to patients on serotonergic medications.

**Serotonin Syndrome Symptoms:**
- Mental status changes (agitation, confusion, hallucinations)
- Autonomic instability (tachycardia, hyperthermia, diaphoresis)
- Neuromuscular symptoms (tremor, rigidity, myoclonus)
- Can progress to seizures, coma, death

**Market Reality:** Approximately 13% of US adults take antidepressants. Including MB in a consumer supplement creates unacceptable risk of serotonin syndrome in a significant portion of potential users.

---

### 4.2 Absolute Contraindication: G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately **400 million people worldwide** and ~2-3% of the US population.

**Mechanism of Harm:**
- MB requires NADPH to function
- G6PD deficiency → insufficient NADPH production
- MB administration → NADPH depletion → hemolytic anemia
- Can cause severe, life-threatening hemolysis

**Affected Populations (Higher Prevalence):**
- African descent (~10-14%)
- Mediterranean descent (~4-12%)
- Middle Eastern descent (~5-10%)
- Southeast Asian descent (~variable)

**NTRPX Implication:** Including MB would require either: (1) mandatory G6PD testing before purchase, or (2) accepting risk of causing hemolytic anemia in ~2-10% of users depending on demographics.

---

### 4.3 Other Safety Considerations

| Concern | Details | Risk Level |
|---------|---------|------------|
| **Blue urine/stool** | Expected, harmless | Low (cosmetic) |
| **GI upset** | Nausea, abdominal discomfort | Low-Moderate |
| **Pregnancy** | Category X teratogen (intra-amniotic data) | ⛔ Contraindicated |
| **Nursing** | Unknown excretion in breast milk | ⚠️ Avoid |
| **Renal impairment** | Reduced clearance | ⚠️ Dose adjustment needed |
| **High-dose toxicity** | Methemoglobinemia, cardiac effects | At doses >7 mg/kg |
| **Photosensitivity** | MB is a photosensitizer | Low at oral doses |

---

## 5. NTRPX Systems Fit Analysis

### 5.1 All Systems Go: Boost

| Criterion | Methylene Blue | NTRPX Standard | Pass/Fail |
|-----------|---------------|----------------|-----------|
| Acute cognitive enhancement | 7% memory improvement (1 RCT, n=26) | Multiple independent RCTs | ❌ FAIL |
| Energy/alertness | Theoretical (mitochondrial) | Proven acute effect | ❌ FAIL |
| Safety for daily use | MAO-A inhibition, drug interactions | Broad population safety | ❌ FAIL |
| Synergy with existing stack | Unknown; potential conflicts | Demonstrated compatibility | ❌ FAIL |

**Verdict for Boost:** DOES NOT FIT

---

### 5.2 All Systems Go: Sustain

| Criterion | Methylene Blue | NTRPX Standard | Pass/Fail |
|-----------|---------------|----------------|-----------|
| Chronic cognitive support | 1 study (PTSD, not healthy) | Long-term RCTs in target population | ❌ FAIL |
| Neuroprotection | Strong preclinical, limited human | Human validation required | ⚠️ INSUFFICIENT |
| Safe for long-term use | Unknown; no chronic studies in healthy adults | Long-term safety data | ❌ FAIL |
| Consistent dosing | Hormetic curve requires precision | Forgiving dose-response | ❌ FAIL |

**Verdict for Sustain:** DOES NOT FIT

---

### 5.3 All Systems Go: Recover

| Criterion | Methylene Blue | NTRPX Standard | Pass/Fail |
|-----------|---------------|----------------|-----------|
| Recovery enhancement | Zero human studies | RCTs showing recovery benefits | ❌ FAIL |
| Anti-inflammatory | Preclinical only | Human inflammation data | ❌ FAIL |
| Sleep quality | No data | Sleep architecture studies | ❌ FAIL |
| Muscle recovery | No data | Recovery biomarker studies | ❌ FAIL |

**Verdict for Recover:** DOES NOT FIT

---

### 5.4 Sprint Systems

| Criterion | Methylene Blue | NTRPX Standard | Pass/Fail |
|-----------|---------------|----------------|-----------|
| Acute performance | Zero RCTs | Demonstrated acute ergogenic effect | ❌ FAIL |
| Exercise capacity | Zero RCTs | VO2max/TTE/power studies | ❌ FAIL |
| Endurance | Theoretical only | Human endurance trials | ❌ FAIL |
| WADA compliance | Not prohibited | Clean status | ✅ PASS |
| Safety in exercise | Unknown | Safe under exertion | ❌ UNKNOWN |

**Verdict for Sprint:** DOES NOT FIT

---

## 6. Verdict & Rationale

### 6.1 Final Recommendation

```
┌─────────────────────────────────────────────────────────────────┐
│                                                                 │
│   RECOMMENDATION: DO NOT INCLUDE IN NTRPX SYSTEMS               │
│                                                                 │
│   Confidence: HIGH                                              │
│                                                                 │
│   Applies to: All Systems Go (Boost, Sustain, Recover)          │
│               Sprint Systems                                     │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 6.2 Evidence Gap Analysis

**What would be needed to reconsider:**

| Gap | Current State | Required Evidence |
|-----|---------------|-------------------|
| Independent replication | 0 studies outside Gonzalez-Lima lab | ≥2 independent RCTs showing cognitive enhancement |
| Sample size | n=26 (largest healthy adult study) | n≥100 adequately powered study |
| Chronic dosing | No long-term data in healthy adults | ≥12-week chronic administration study |
| Exercise performance | Zero studies | ≥1 RCT with performance endpoints |
| Drug interaction mitigation | MAO-A inhibition is intrinsic | Cannot be mitigated without changing the molecule |
| G6PD risk | ~2% population contraindicated | Cannot be mitigated in consumer product |

### 6.3 Comparison to NTRPX Standards

| NTRPX Principle | Methylene Blue Status |
|-----------------|----------------------|
| "Evidence over theory" | ❌ Strong theory, weak human evidence |
| "Proven over promising" | ❌ Promising mechanism, unproven in target use |
| "No compromises on safety" | ❌ MAO-A inhibition, G6PD contraindication |
| "Independent replication required" | ❌ Single research group |
| "Target population validation" | ❌ Mostly disease states, not optimization |
| "Broad population applicability" | ❌ Excludes SSRI users (~13%), G6PD deficient (~2%) |

### 6.4 Why the Biohacker Enthusiasm is Misleading

Methylene blue has gained significant popularity in biohacker communities based on:

1. **Mechanistic elegance** - The mitochondrial electron cycling mechanism is scientifically compelling
2. **Historical pedigree** - 140+ years of medical use
3. **Subjective reports** - User testimonials (not controlled data)
4. **Influencer promotion** - High-profile endorsements without evidence review
5. **Longevity association** - Connection to mitochondrial health/aging research

**The problem:** None of this constitutes evidence of efficacy for cognitive or physical performance enhancement in healthy adults. The biohacker community has conflated "interesting mechanism" with "proven benefit."

### 6.5 Appropriate Use Cases (Outside NTRPX)

Methylene blue does have legitimate applications:

| Use Case | Evidence Level | Appropriate? |
|----------|---------------|--------------|
| Methemoglobinemia (medical) | FDA-approved | ✅ Yes |
| Vasoplegic syndrome (medical) | Clinical evidence | ✅ Yes |
| Research tool | N/A | ✅ Yes |
| Individual biohacker experimentation | N/A | Personal risk acceptance |
| **Consumer supplement product** | Insufficient | ❌ No |

---

## 7. References

### Primary Clinical Studies

1. Rodriguez P, Zhou W, Barrett DW, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. *Radiology*. 2016;281(2):516-526. [PMC5084971]

2. Rodriguez P, Singh AP, Malloy KE, et al. Methylene blue modulates functional connectivity in the human brain. *Neuroimage Clin*. 2017;15:252-257. [PMC5018244]

3. Telch MJ, Bruchey AK, Rosenfield D, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. *Am J Psychiatry*. 2014;171(10):1091-1098.

4. Zoellner LA, Telch M, Foa EB, et al. Enhancing Extinction Learning in Posttraumatic Stress Disorder With Brief Daily Imaginal Exposure and Methylene Blue. *J Clin Psychiatry*. 2017;78(7):e782-e789.

5. Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. *J Alzheimers Dis*. 2015;44(2):705-720.

6. Deng Y, Wang R, Li S, et al. Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery. *J Clin Anesth*. 2021;68:110108.

### Mechanism & Review Articles

7. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. *Prog Neurobiol*. 2012;96(1):32-45. [PMC3265679]

8. Tucker D, Lu Y, Zhang Q. From Mitochondrial Function to Neuroprotection—An Emerging Role for Methylene Blue. *Mol Neurobiol*. 2018;55(6):5137-5153. [PMC5826781]

9. Gonzalez-Lima F, Auchter A. Protection against neurodegeneration with low-dose methylene blue and near-infrared light. *Front Cell Neurosci*. 2015;9:179. [PMC4428125]

10. Bruchey AK, Gonzalez-Lima F. Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue. *Am J Pharmacol Toxicol*. 2008;3(1):72-79. [PMC2867617]

### Safety & Drug Interactions

11. Gillman PK. Methylene blue implicated in potentially fatal serotonin toxicity. *Anaesthesia*. 2006;61(10):1013-1014.

12. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. *Br J Pharmacol*. 2007;152(6):946-951. [PMC2078225]

13. FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue and serotonergic psychiatric medications. 2011.

14. Methylene Blue - StatPearls. NCBI Bookshelf. [NBK557593]

15. Blue cures blue but be cautious. *J Lab Physicians*. 2011;3(2):127-129. [PMC3249703]

---

## Document Control

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0 | 2026-01-23 | NTRPX R&D | Initial comprehensive evaluation |

---

*This document represents NTRPX's internal evaluation based on available clinical evidence as of the document date. The recommendation to exclude methylene blue from NTRPX Systems is based on the compound's failure to meet NTRPX's evidence standards, not a judgment on its potential for future development or individual biohacker use.*